News

 

Nerviano Medical Sciences Announces Enhanced US Executive Team: Terrence West, MBA, Expands Role as Chief Operating Officer

Nerviano Medical Sciences Announces Enhanced US Executive Team: Terrence West, MBA, Expands Role as Chief Operating Officer

NERVIANO, IT and BOSTON, Mass., August 1, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group), focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the expansion of and transition in its executive team of its wholly owned U.S. subsidiary (Nerviano Medical Sciences, Inc./ NMS-US) in Boston. Terrence West, MBA, the company’s New Business, Virtual CEO has been appointed to the newly created position of Chief Operating Officer, effective immediately, to further drive the growth of NMS-US while continuing to oversee the strategic positioning of NMS-173, its IDH1/IDH2 Inhibitor Asset.

(Click the title for the complete article)

Nerviano Medical Sciences Announces FDA Clearance of Investigational New Drug (IND) for NMS-03592088 in positive Relapsed or Refractory Acute Myeloid Leukemia

Nerviano Medical Sciences Announces FDA Clearance of Investigational New Drug (IND) for NMS-03592088 in positive Relapsed or Refractory Acute Myeloid Leukemia

Nerviano 22 June 2023_Nerviano Medical Sciences Srl (NMS), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is delighted to announce the FDA Clearance of Investigational New Drug (IND) Application for NMS-03592088 (NMS-088), a novel, potent FLT3 inhibitor.

(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. to Present MPSA-153-001 at ASCO 2023: Slide deck, Poster and Video Preview

Nerviano Medical Sciences S.r.l. to Present MPSA-153-001 at ASCO 2023: Slide deck, Poster and Video Preview

Nerviano, 26 May 2023 – Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, published a poster today, describing the currently enrolling phase II part of the trial MPSA-153-001, will be presented at the upcoming ASCO Annual Meeting which will be held June 2-6, 2023 at the McCormick Place, Chicago, IL.

(Click the title for the complete article)

Nerviano Medical Sciences Appointed Paramjit Kaur, PhD to Accelerate PERK/GCN2 Inhibitor Asset Development

Nerviano Medical Sciences Appointed Paramjit Kaur, PhD to Accelerate PERK/GCN2 Inhibitor Asset Development

NERVIANO, May 17th 2023 – Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Paramjit Kaur, PhD has joined the Global Asset Leadership Team to lead the strategy and the development of clinical PERK/GCN2 asset currently in phase 1.

(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. to Present at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Nerviano Medical Sciences S.r.l. to Present at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Nerviano, 15 May 2023 – Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that a poster, describing the currently enrolling phase II part of the trial M
PSA-153-001, will be presented at the upcoming ASCO Annual Meeting which will be held June 2-6, 2023 at the McCormick Place, Chicago, IL.
(Click the title for the complete article)

1st European Cancer Dependency Map Symposium successfully concluded in Milan on May 9th, sponsored by Nerviano Medical Sciences Srl

1st European Cancer Dependency Map Symposium successfully concluded in Milan on May 9th, sponsored by Nerviano Medical Sciences Srl

Nerviano 9 May 2023_ Nerviano Medical Sciences Srl (NMS) was delighted to be the title sponsor of  the 1st European Cancer Dependency Map Symposium, together with Astra Zeneca. This is an international event organized by scientists at Human Technopole, EMBL – European Bioinformatics Institute (Cambridge, UK), Wellcome Sanger Institute (Cambridge, UK) and ETH Zurich (Switzerland) taking place at Human Technopole in Milan on May 8-9, 2023.
(Click the title for the complete article)

Nerviano Medical Sciences included as AACR 2023 Plenary Session highlights for its NMS-03592088 Phase 1 Clinical Trial Data in Patients with FLT3 positive Relapsed or Refractory Acute Myeloid Leukemia

Nerviano Medical Sciences included as AACR 2023 Plenary Session highlights for its NMS-03592088 Phase 1 Clinical Trial Data in Patients with FLT3 positive Relapsed or Refractory Acute Myeloid Leukemia

Nerviano 21 April 2023_Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is delighted to be selected as Plenary Session highlights of the AACR (American Association for Cancer Research) Annual Meeting 2023 for the data from the First-In-Human study of NMS-03592088 – a novel, potent inhibitor of FLT3, KIT and CSF1R. The Phase 1 clinical trial data were presented during an oral scientific session on 16 April.
(Click the title for the complete article)

Nerviano Medical Sciences Announces Phase 1 Clinical Trial Data for NMS-03592088 in Patients with FLT3 positive Relapsed or Refractory Acute Myeloid Leukemia

Nerviano Medical Sciences Announces Phase 1 Clinical Trial Data for NMS-03592088 in Patients with FLT3 positive Relapsed or Refractory Acute Myeloid Leukemia

Nerviano 16 April 2023_Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that data from the First-In-Human study of NMS-03592088, a novel, potent inhibitor of FLT3, KIT and CSF1R were presented during an oral scientific session at the American Association for Cancer Research 2023 Annual Meeting in Orlando, Florida.
(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. to Present New Preclinical Data for NMS-812 and NMS-0963 at the American Association for Cancer Research (AACR) 2023 Annual Meeting

Nerviano Medical Sciences S.r.l. to Present New Preclinical Data for NMS-812 and NMS-0963 at the American Association for Cancer Research (AACR) 2023 Annual Meeting

Nerviano, 05 April 2023 – Nerviano Medical Sciences Srl,a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that two posters will be presented at the upcoming AACR annual meeting which will be held April 14-19, 2023 at the Orange County Convention Center, Orlando, Florida.
(Click the title for the complete article)

 

Welcome and Check out our new motion picture!

WATCH OUR VIDEO